Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer

Release Date: April 30, 2024

Expiration Date: April 30, 2025

Activity Overview

For patients with HR+/HER2- early-stage breast cancer (eBC), endocrine therapy represents the mainstay of adjuvant therapy. Options for higher risk disease historically included adjuvant chemotherapy, and/or extending endocrine therapy from 5 to 10 years. However, in recent years, options for high-risk patients have expanded to include CDK4/6 inhibitors, and PARP inhibitors for patients with germline BRCA1/2 mutations. Additional approaches, such as immune checkpoint inhibitors and antibody-drug conjugates, are also being explored.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Medical Crossfire®: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early Stage HR+, HER2- Breast Cancer symposium, held in March 2024. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with HR+/HER2- eBC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Target Audience

This educational activity is directed toward physicians and other health care professionals involved in the treatment of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate biomarkers to assess recurrence risk and develop multidisciplinary treatment plans for patients with early-stage HR+/HER2- breast cancer
• Assess emerging data from clinical trials investigating systemic therapies for patients with early-stage HR+, HER2- breast cancer and the placement of therapies into evolving treatment paradigms
• Integrate recent evidence from clinical trials of systemic therapies, along with expert guidelines, into multidisciplinary treatment planning for individual
• Develop plans to optimize outcomes and improve patient quality of life by mitigating, monitoring for, and managing adverse events in patients undergoing treatment for early-stage HR+, HER2-breast cancer

The staff of Physicians’ Education Resource, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.